^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CDK6 inhibitor

    Related drugs:
    12h
    MONARCH plus: A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer (clinicaltrials.gov)
    P3, N=463, Active, not recruiting, Eli Lilly and Company | Trial completion date: Jan 2027 --> Mar 2028
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 overexpression • HER-2 negative
    |
    Verzenio (abemaciclib) • fulvestrant • letrozole • anastrozole
    15h
    A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (clinicaltrials.gov)
    P1, N=136, Recruiting, Genentech, Inc. | Trial completion date: Jul 2029 --> Apr 2030 | Trial primary completion date: Jul 2029 --> Apr 2030
    Trial completion date • Trial primary completion date • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    giredestrant (RG6171) • omeprazole
    3d
    Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype (clinicaltrials.gov)
    P3, N=248, Not yet recruiting, Fudan University
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • HER-2 expression • HER-2 underexpression • PGR positive
    |
    trastuzumab rezetecan (SHR-A1811) • famitinib (SHR 1020)
    3d
    MONARCH 3: A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer (clinicaltrials.gov)
    P3, N=493, Active, not recruiting, Eli Lilly and Company | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative
    |
    Verzenio (abemaciclib) • letrozole • anastrozole
    6d
    ‌A Phase II, Two-Stage Study Evaluating the Efficacy of Entinostat in Combined with Fulvestrant in Locally Advanced or Metastatic Breast Cancer with Recurrence or Progression after CDK4/6 Inhibitor plus Endocrine Therapy (ChiCTR2500114131)
    P=N/A, N=50, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 negative
    |
    fulvestrant • Jingzhuda (entinostat)
    6d
    An open-label, positive drug-controlled, parallel-group, multicenter phase II clinical trial on the efficacy, safety and pharmacokinetics of flonoltinib maleate tablet in patients with intermediate and high-risk myelofibrosis (ChiCTR2500115640)
    P2, N=75, Completed, Institute of Hematology, Chinese Academy of Medical Sciences / West China Hospital of Sichuan University; Chengdu Zenitar Biomedical Technology Co., L
    New P2 trial
    |
    flonoltinib
    6d
    Phase IIa study on the safety and efficacy of Flonoltinib Maleate Tablets in the treatment of patients with polycythemia vera (ChiCTR2500111413)
    P2, N=60, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS);West China Hospital of Sichuan University;Shengjin
    New P2 trial
    |
    hydroxyurea • flonoltinib
    6d
    Food Effect Study in Healthy Volunteers of Phase I Flonoltinib Maleate (ChiCTR2500115039)
    P1, N=24, Completed, Chengdu Xinhua Hospital; Chengdu Zenitar Biomedical Technology Co.Ltd.
    New P1 trial
    |
    flonoltinib
    9d
    Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=28, Recruiting, The Methodist Hospital Research Institute | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    Verzenio (abemaciclib) • fulvestrant
    11d
    DNACDKHR: CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment (clinicaltrials.gov)
    P2, N=158, Not yet recruiting, Peking University People's Hospital
    New P2 trial • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    16d
    CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS) (clinicaltrials.gov)
    P3, N=1903, Recruiting, Fudan University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive • HER-2 amplification • PGR positive
    |
    tamoxifen • letrozole • exemestane
    21d
    postMONARCH: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer (clinicaltrials.gov)
    P3, N=368, Active, not recruiting, Eli Lilly and Company | Trial completion date: Feb 2026 --> Dec 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Verzenio (abemaciclib) • fulvestrant